Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Thrombolytic Science International LLC
DescriptionCombination product of a recombinant form of pro-urokinase with one amino acid mutation administered with a plasma complement 1 (C1) esterase inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationStroke
Indication DetailsTreat acute ischemic stroke
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today